iQur

iQur is a London-based biotechnology company developing vaccines using its proprietary tandem core virus-like particle platform.

The technology uses the hepatitis B virus core protein to display multiple antigens simultaneously, stimulating strong immune responses without the risks of live or attenuated viruses.

iQur's pipeline spans vaccine candidates for influenza, malaria, dengue fever, hepatitis and Burkholderia, alongside molecular diagnostics work, and serves the wider vaccine research and public health community.